Differential immunogenicity of homologous versus heterologous boost in Ad26.COV2.S vaccine recipients
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
No abstract available
Article activity feed
-
-
SciScore for 10.1101/2021.10.14.21264981: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics Consent: Study approval: All donors provided written consent.
IRB: The study was conducted in accordance with the Declaration of Helsinki and approved by the NUS Institutional Review Board (NUS-IRB-2021-292), the SingHealth Centralised Institutional Review Board (CIRB ref.:Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Table 2: Resources
Antibodies Sentences Resources Surrogate Virus Neutralization Test (sVNT): The sVNT assay is a proxy measurement of antibodies inhibiting SARS-CoV-2 virus binding to the host cell receptor, human angiotensin-converting enzyme 2 (hACE2), and has been shown to correlate closely with antibody … SciScore for 10.1101/2021.10.14.21264981: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics Consent: Study approval: All donors provided written consent.
IRB: The study was conducted in accordance with the Declaration of Helsinki and approved by the NUS Institutional Review Board (NUS-IRB-2021-292), the SingHealth Centralised Institutional Review Board (CIRB ref.:Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Table 2: Resources
Antibodies Sentences Resources Surrogate Virus Neutralization Test (sVNT): The sVNT assay is a proxy measurement of antibodies inhibiting SARS-CoV-2 virus binding to the host cell receptor, human angiotensin-converting enzyme 2 (hACE2), and has been shown to correlate closely with antibody neutralization of SARS-CoV-2 (23). hACE2suggested: NonePercent inhibition of RBD-hACE2 binding was computed using the following equation: SARS-CoV-2-specific Luminex Antibody assay: Antigen-specific IgG and IgA responses in serum samples were measured using a previously described bead-based immune-assay with some adjustments (22). Antigen-specific IgGsuggested: NoneMFI values of serum samples were converted to antibody quantity (i.e. g/ml) using anti-Spike IgG and IgA antibody standards (AcroBiosystems). anti-Spike IgGsuggested: NoneIgAsuggested: NoneNext, cells were stained with an antibody cocktail (against CD3, CD10, CD19, CD21, CD27, CD38, CD40, CD69, CD71, CD95, IgD, IgG, IgM, see Table S1) for 30 mins at 4°C. CD3suggested: NoneCD10suggested: NoneCD19suggested: (BD Biosciences Cat# 558063, RRID:AB_2275535)CD21suggested: (IMGENEX Cat# DDX0120, RRID:AB_1929894)CD27suggested: NoneCD38suggested: (Gonzalez Lab; Facultad de QuÃmica; Universidad de la República; Uruguay Cat# INQ-T10, RRID:AB_2721895)CD40suggested: NoneCD69suggested: NoneCD71suggested: (Thermo Fisher Scientific Cat# MHCD9528TR, RRID:AB_2539765)CD95suggested: NoneIgD, IgGsuggested: NoneSoftware and Algorithms Sentences Resources Briefly, SARS-CoV-2 recombinant proteins Spike, S1 or S2 (AcroBiosystems) were covalently conjugated to Magpix Luminex beads. AcroBiosystemssuggested: (ACRObiosystems, RRID:SCR_012550)Analysis of flow cytometry data was performed using FlowJo software, version 10 (BD). FlowJosuggested: (FlowJo, RRID:SCR_008520)Statistical analyses: All statistical analyses were performed in Prism (GraphPad Software); details are provided in the figure legends. Prismsuggested: (PRISM, RRID:SCR_005375)GraphPadsuggested: (GraphPad Prism, RRID:SCR_002798)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:There are some important limitations in our study. In addition to the small sample size, the cross-sectional nature of the study did not allow to precisely evaluate the modification of Spike-specific T cell frequency induced by the second dose at individual level. Furthermore, the analysis of both humoral and cellular immunity was performed at different time points after vaccination. Even though we showed that the level of Spike-specific T cells was minimally reduced within the first 6 months after vaccination and did not appear to influence the different pattern of Spike-specific T cells, an analysis at identical time points after boosting is indicated to demonstrate the enhanced immunogenicity of heterologous vaccination and its durability over time. Finally, the limited quantity of PBMCs collected only allowed us to perform a simple ELISpot analysis of the T cell response, a method that cannot discriminate whether the Spike-specific T cells induced by different vaccination regimens are CD4 or CD8 T cells. Such information would be needed to better characterize the possible further qualitative differences in T cells responses induced by the different vaccination regimens. In conclusion, while the Ad26.COV2.S vaccine has been initially proposed as a single dose vaccine, the progressive reduction of its protective efficacy against SARS-CoV-2 infection over time have warranted a better definition of the best boosting strategy (12). Here we provide data that demonstrate the enh...
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
-
